Imaging agent CSB-321 for cancer immunotherapy
Part of Cancer clinical trials.
This study tests a new imaging agent (called CSB-321) to see how well it can find cancer cells in people who are already receiving immunotherapy. It may help doctors understand which tumors are responding to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced cancer that has spread (metastatic) and are being treated with certain immunotherapy drugs (checkpoint inhibitors) or, if you have uveal melanoma, with tebentafusp-tebn.
- You have at least one tumor that is 15 mm or larger (about the size of a grape) or two tumors each 15 mm or larger, and you are willing to have a biopsy of one of them.
- You are able to do most of your daily activities (ECOG score 0 to 2).
- Your life expectancy is more than 6 months.
- You are willing and able to undergo all study procedures, including CT scans and blood draws.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This study is testing an investigational drug called SG1827, either alone or combined with other standard immunotherapy medicines, for advanced solid tumors. The goal is to see if this combination can help shrink or slow the growth of the tumor.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.